[Vitreous metastasis of malignant cutaneous melanoma during treatment with ipilimumab]

Ophthalmologe. 2017 Feb;114(2):163-166. doi: 10.1007/s00347-016-0271-3.
[Article in German]

Abstract

An isolated metastasis of the vitreous body from a malignant cutaneous melanoma without involvement of the choroid is an extremely rare occurrence. We report on the case of a 59-year-old female patient who presented with a vitreous body metastasis during systemic treatment with the anti-cytotoxic T lymphocyte-associated antigen (anti-CTLA 4) antibody ipilimumab. This case report underlines the diagnostic difficulties in such cases and points out the risk of metastasis in immune-privileged sites under systemic immunotherapy.

Keywords: Ipilimumab; Malignant melanoma; Vitrectomy; Vitreous body; Vitreous metastasis.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Diagnosis, Differential
  • Eye Neoplasms / chemically induced*
  • Eye Neoplasms / pathology
  • Eye Neoplasms / secondary*
  • Female
  • Humans
  • Ipilimumab
  • Melanoma / chemically induced*
  • Melanoma / pathology*
  • Middle Aged
  • Skin Neoplasms / complications
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Treatment Outcome
  • Vitreous Body / drug effects
  • Vitreous Body / pathology*

Substances

  • Antibodies, Monoclonal
  • Ipilimumab